A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites against .

is responsible for a wide range of gastric diseases, including gastric cancer and gastritis. With half of the world's population infected by and the current standard of care associated with suboptimal outcomes, a search for more effective drugs is critical. To facilitate drug screening for , we developed a microtiter plate-based compound screening method that is faster and can screen multiple compounds.